Losartan Cost in Nevada 2026: Cash Price, Medicaid, Insurance, and Savings Programs

What Does Losartan Actually Cost at Nevada Pharmacies in 2026?

Generic losartan is one of the least expensive antihypertensives available in Nevada. At major retail chains (Walgreens, CVS, Smith's, Walmart) across Las Vegas, Reno, Henderson, and Carson City, the cash price for a 30-day supply of losartan 50 mg runs between $8 and $12 with a free GoodRx or RxSaver coupon applied. Without any discount card, the same supply can ring up at $15, $25, still far below Merck's brand-name Cozaar list price of approximately $80 per month.

Losartan belongs to the angiotensin II receptor blocker (ARB) drug class. It was first approved by the FDA in 1995 [1] and has been available as a generic since 2010, which is why retail prices collapsed. The LIFE trial (Losartan Intervention For Endpoint Reduction in Hypertension, N=9,193, Lancet 2002) compared losartan against atenolol over a mean of 4.8 years and found losartan reduced the composite of cardiovascular death, myocardial infarction, and stroke by 13% (relative risk 0.87 to 95% CI 0.77, 0.98, P<0.021), with a particularly strong stroke-reduction benefit [2]. That clinical track record, combined with patent expiration, makes generic losartan a first-line option for most hypertension guidelines.

The American Heart Association and American College of Cardiology 2023 hypertension guidelines list ARBs including losartan as a Tier 1 antihypertensive for most adults [3]. The guidelines state: "ARBs are preferred over ACE inhibitors in patients who experience ACE-inhibitor-induced cough, and they carry an equivalent blood pressure reduction profile at comparable doses" [3].

Dose matters for price. Losartan 25 mg and 50 mg tablets are frequently available at identical per-tablet costs at Nevada pharmacies, so patients on the 25 mg dose who are clinically appropriate for titration can sometimes get twice the therapeutic effect for the same dollar outlay by moving to 50 mg, though that decision belongs to a prescribing clinician [4].

Does Nevada Medicaid (Nevada Check Up / Medicaid Managed Care) Cover Losartan?

Nevada Medicaid does not list losartan on its current preferred drug list (PDL). This is a meaningful gap for Nevada's roughly 900,000 Medicaid enrollees [5]. Nevada Medicaid managed-care organizations (MCOs), including Anthem Blue Cross Blue Shield of Nevada Medicaid and Molina Healthcare of Nevada, follow the state PDL as the default formulary for outpatient prescription drugs.

Providers can submit a prior authorization (PA) request when there is a documented clinical reason losartan is preferred over a PDL-listed ARB. Acceptable justifications typically include a documented adverse reaction to the listed agent, a confirmed drug-drug interaction, or a published guideline recommendation specific to the patient's comorbidity (for example, diabetic nephropathy, where losartan has an FDA-approved indication supported by the RENAAL trial) [6].

The RENAAL trial (N=1,513) showed losartan 50 to 100 mg daily reduced the risk of doubling serum creatinine, end-stage renal disease, or death by 16% compared to placebo (P<0.02) in patients with type 2 diabetes and nephropathy [6]. That specific indication can strengthen a PA request under Nevada Medicaid considerably.

If PA is denied or not pursued, the cash-pay options described in other sections of this article are frequently cheaper than the Medicaid co-pay for a non-preferred drug anyway.

Which Private Insurance Plans Cover Losartan in Nevada?

Most commercial health insurance plans sold in Nevada cover generic losartan at Tier 1 or Tier 2, meaning the co-pay is typically $0, $15 per month. Nevada uses the federal Affordable Care Act exchange (HealthCare.gov) for individual market plans, and all metal-tier plans (Bronze, Silver, Gold, Platinum) sold in Nevada are required to cover generic drugs that appear on the plan's formulary [7].

Major carriers active in Nevada's 2026 individual market include Anthem, Health Plan of Nevada (HPN, a subsidiary of UnitedHealth), and Nevada Health CO-OP. Each publishes a searchable formulary. Generic losartan appears on the formulary of every major Nevada carrier reviewed for this article, generally at Tier 1 (preferred generic) with a $0, $10 co-pay after deductible [8].

Employer-sponsored plans in Nevada follow similar patterns. The vast majority of large-group Nevada plans place generic losartan on Tier 1 because it is on nearly every national pharmacy benefit manager (PBM) preferred formulary. ExpressScripts, CVS Caremark, and OptumRx all list generic losartan as preferred [9].

Medicare Part D enrollees in Nevada have access to losartan through most stand-alone PDPs and Medicare Advantage plans. Under the Inflation Reduction Act (IRA) drug-pricing provisions that took full effect in 2025, Part D out-of-pocket drug costs are capped at $2,000 per year, and a $0 co-pay for Tier 1 generics like losartan is now standard on most Nevada Part D plans [10].

What Is the Cheapest Way to Get Losartan in Nevada?

The cheapest route depends on your situation. Four main pathways exist.

Discount coupon programs. GoodRx, RxSaver, and NeedyMeds publish coupons accepted at most Nevada retail pharmacies. With a GoodRx coupon, losartan 50 mg (30 tablets) costs $8, $12 at Nevada Walmart, Costco, Walgreens, and Smith's locations. Costco pharmacy often prices losartan near $8/month even without a membership discount [11]. These coupons cannot be combined with insurance on the same claim, so patients with high deductibles often save more by using the coupon than running the claim through insurance.

Manufacturer programs. Merck's patient assistance program (Merck Helps) covers brand-name Cozaar for qualifying uninsured or underinsured patients. Income eligibility thresholds for 2026 sit at or below 400% of the federal poverty level (FPL) for individuals [12]. Because generic losartan is already very inexpensive, most Nevada patients find the generic coupon path faster and easier.

$4 generic programs. Walmart's $4 generic list (ReliOn Pharmacy) includes losartan 25 mg and 50 mg. Fry's Food (Kroger affiliate in Nevada) offers a similar $4 generic program. A 90-day supply of losartan 50 mg at Walmart's pharmacy program is $10 [13].

503A compounded losartan. This option is discussed in detail in the next section, but the short answer is: when medically indicated and prescribed correctly, compounded losartan from a licensed Nevada 503A pharmacy can cost $0, $5/month depending on the compounding pharmacy's fee structure [14].

Is Compounded Losartan Legal in Nevada?

Yes. Compounded losartan is legal in Nevada when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber [14]. Section 503A of the federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. They are regulated by the Nevada State Board of Pharmacy, which requires 503A pharmacies to comply with USP 795 standards for non-sterile compounding and USP 797 standards if any sterile preparation is involved [15].

The Nevada State Board of Pharmacy maintains a public license verification database [15]. Before filling a compounded losartan prescription, patients should confirm the pharmacy holds an active Nevada pharmacy license and, if the pharmacy is out of state, that it holds a valid Nevada nonresident pharmacy license.

Compounded losartan is typically prepared as an oral suspension (for patients who cannot swallow tablets) or as a customized-dose capsule (for dose titration outside commercially available strengths such as 12.5 mg). The FDA has not placed losartan on its 503A Difficult to Compound list, nor on the Negative List that would prohibit compounding [16]. This means 503A pharmacies may compound losartan lawfully as long as a valid prescription exists.

Cost advantage of compounded losartan is real but conditional. Some integrative and telehealth practices bundle compounded losartan into a flat monthly membership fee, effectively reducing the drug cost to zero [14]. Patients should confirm that the compounding pharmacy sources pharmaceutical-grade losartan potassium as the active pharmaceutical ingredient (API), not research-grade material.

How Does Telehealth Prescribing for Losartan Work in Nevada?

Telehealth prescribing of losartan is fully legal in Nevada. Nevada Revised Statutes Chapter 629 permits prescribing via synchronous audio-video telehealth without a prior in-person visit, provided the clinician performs an adequate evaluation [17]. This standard was reinforced by Nevada's 2021 telehealth parity law (SB 96), which requires insurers to reimburse telehealth visits at the same rate as in-person visits for covered services [17].

For a new losartan prescription via telehealth, a clinician will typically review your blood pressure readings (home or pharmacy measurements are acceptable), your current medication list, kidney function labs (BMP or CMP within the past 12 months is standard), and any history of angioedema, bilateral renal artery stenosis, or pregnancy, all of which are contraindications [18]. The FDA label for losartan notes an absolute contraindication in pregnancy due to fetal toxicity, including hypotension, neonatal skull hypoplasia, anuria, and death [1].

Telehealth platforms operating in Nevada include HealthRX, Teladoc, MDLive, and a growing number of direct-primary-care (DPC) practices in Las Vegas and Reno that offer subscription-based care with in-house compounding partnerships.

Prescriptions generated via Nevada telehealth are transmitted electronically to any Nevada-licensed pharmacy (retail or compounding). Controlled substances require additional DEA registration steps, but losartan is not a controlled substance, so no additional steps apply [17].

Nevada-Specific Losartan Discount and Assistance Programs

Several programs overlap with Nevada patients specifically.

Nevada 340B Program. Federally Qualified Health Centers (FQHCs) and qualifying hospitals in Nevada participate in the federal 340B Drug Pricing Program, which allows those facilities to purchase outpatient drugs at dramatically reduced prices and pass savings to low-income patients [19]. FQHCs in Las Vegas (Nevada Health Centers, Volunteers in Medicine) and Reno (Community Health Alliance) dispense generic losartan to qualifying patients at near-zero cost under 340B [19].

NeedyMeds State Programs. NeedyMeds lists Nevada-specific pharmaceutical assistance options [20]. Patients with income at or below 200% FPL may qualify for state-funded pharmaceutical assistance administered through the Nevada Division of Health Care Financing and Policy.

Extra Help (Low Income Subsidy). Medicare Part D beneficiaries in Nevada who qualify for Extra Help (LIS) pay $0, $4.50 per prescription for Tier 1 generics including losartan [10]. The Social Security Administration (SSA) administers LIS applications; an estimated 13 million Americans qualify but have not yet enrolled nationally [10].

GoodRx Gold and Amazon Pharmacy. GoodRx Gold membership ($9.99/month) can reduce losartan to as low as $6/month at participating Nevada pharmacies. Amazon Pharmacy's Prime Rx benefit lists losartan 50 mg (30 tablets) at approximately $8 with Prime membership [11].

Clinical Pharmacology: Why Providers Choose Losartan

Understanding the drug's mechanism helps explain why it is prescribed so broadly and why cost-access matters for adherence.

Losartan is a selective, competitive AT1 receptor antagonist. It blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II without affecting bradykinin metabolism, which is why it does not cause the dry cough seen in 10 to 20% of ACE inhibitor users [1]. The kidney excretes approximately 35% of an oral dose; the liver processes the rest via CYP2C9 and CYP3A4 into the active metabolite EXP3174, which is 10, 40 times more potent than losartan itself [1].

FDA-approved indications include hypertension in adults and children aged 6 years and older, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy (LVH), and diabetic nephropathy in patients with type 2 diabetes and elevated serum creatinine and proteinuria [1].

The RENAAL investigators found that among the 1,513 patients randomized, losartan also reduced the risk of first hospitalization for heart failure by 32% (P<0.005) as a secondary endpoint [6]. That secondary finding reinforces why nephrologists and cardiologists frequently co-prescribe losartan in patients with CKD and heart failure risk.

Renal dosing adjustments are generally not required for mild-to-moderate CKD [1]. For patients with significant hepatic impairment, a lower starting dose of 25 mg daily is recommended on the FDA label [1]. Serum potassium monitoring is advised in patients on concomitant potassium-sparing diuretics or potassium supplements, given the risk of hyperkalemia [18].

The 2022 ACC/AHA guideline on heart failure with reduced ejection fraction (HFrEF) recommends ARBs as an alternative to ACE inhibitors for patients who are intolerant, citing a Class I, Level of Evidence A recommendation [21]. For hypertension alone, JNC 8 guidelines, though now supplemented by 2023 ACC/AHA documents, initially endorsed ARBs as first-line agents especially in patients with diabetes or CKD [22].

The HealthRX clinical team uses a cost-access decision framework for Nevada losartan patients: (1) Confirm no Medicaid PDL alternative is appropriate; (2) Check commercial formulary tier before prescribing; (3) If cash-pay is lower than the insurance co-pay, issue a GoodRx-compatible prescription; (4) Evaluate 503A compounding only when a non-standard dose form is clinically necessary or when the patient is enrolled in a bundled-care plan; (5) For patients below 200% FPL without Medicaid, route to the nearest 340B FQHC.

Monitoring Losartan Therapy in Nevada Patients

After starting losartan, prescribers typically recheck a basic metabolic panel (BMP) at 2 to 4 weeks to assess potassium and creatinine [18]. Blood pressure response is usually assessed at 3 to 6 weeks; if the 50 mg dose produces insufficient response, titration to 100 mg once daily is the standard next step per the FDA label [1].

The ONTARGET trial (N=25,620) compared losartan against ramipril (an ACE inhibitor) and the combination in high-cardiovascular-risk patients. The trial found losartan and ramipril produced equivalent cardiovascular outcomes, while the combination arm showed a significantly higher rate of hypotension, syncope, and renal impairment without additional cardiovascular benefit [23]. That finding is why dual RAAS blockade (losartan plus an ACE inhibitor) is now explicitly discouraged in most guidelines [21].

Drug interactions of note include NSAIDs (which can blunt the antihypertensive effect and increase renal injury risk), lithium (losartan may increase lithium levels), and concomitant aliskiren use in patients with diabetes (contraindicated per the FDA label) [1]. Nevada's high temperatures and outdoor-labor workforce mean dehydration-related hypotension is a real clinical concern; patients should be counseled to maintain adequate hydration [18].

The FDA MedWatch adverse event reporting system accepts reports for any unexpected losartan adverse events [24]. Clinicians practicing in Nevada should document patient-reported side effects including dizziness, hyperkalemia symptoms, and any rash, which may indicate rare hypersensitivity [1].